These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33589218)

  • 1. Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk.
    Tokgözoğlu L; Casula M; Pirillo A; Catapano AL
    Atheroscler Suppl; 2020 Dec; 42():e1-e5. PubMed ID: 33589218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
    Gencer B; Koskinas KC; Räber L; Karagiannis A; Nanchen D; Auer R; Carballo D; Carballo S; Klingenberg R; Heg D; Matter CM; Lüscher TF; Rodondi N; Mach F; Windecker S
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Studies Do Not Challenge the American College of Cardiology/American Heart Association Lipid Guidelines.
    Hofer TP; Sussman JB; Hayward RA
    Ann Intern Med; 2016 May; 164(10):683-4. PubMed ID: 26857151
    [No Abstract]   [Full Text] [Related]  

  • 4. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
    Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
    Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention.
    Grundy SM; Stone NJ
    JAMA Cardiol; 2019 Jun; 4(6):589-591. PubMed ID: 30994869
    [No Abstract]   [Full Text] [Related]  

  • 6. Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines.
    Koskinas KC; Gencer B; Nanchen D; Branca M; Carballo D; Klingenberg R; Blum MR; Carballo S; Muller O; Matter CM; Lüscher TF; Rodondi N; Heg D; Wilhelm M; Räber L; Mach F; Windecker S
    Eur J Prev Cardiol; 2021 Mar; 28(1):59-65. PubMed ID: 33755142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011.
    Ray KK; Kastelein JJ; Boekholdt SM; Nicholls SJ; Khaw KT; Ballantyne CM; Catapano AL; Reiner Ž; Lüscher TF
    Eur Heart J; 2014 Apr; 35(15):960-8. PubMed ID: 24639424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana L; Plana N; Pérez-Calahorra S; Ibarretxe D; Lamiquiz-Moneo I; Pedro-Botet J; Suárez-Tembra M; Valdivielso P; Ortega E; Civeira F;
    Atherosclerosis; 2017 Jul; 262():107-112. PubMed ID: 28531826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Wójcik C
    Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian?
    Thanassoulis G; Gregoire J; Pearson GJ
    Can J Cardiol; 2019 May; 35(5):558-563. PubMed ID: 31030858
    [No Abstract]   [Full Text] [Related]  

  • 13. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Grundy SM; Stone NJ; Bailey AL; Beam C; Birtcher KK; Blumenthal RS; Braun LT; de Ferranti S; Faiella-Tommasino J; Forman DE; Goldberg R; Heidenreich PA; Hlatky MA; Jones DW; Lloyd-Jones D; Lopez-Pajares N; Ndumele CE; Orringer CE; Peralta CA; Saseen JJ; Smith SC; Sperling L; Virani SS; Yeboah J
    J Am Coll Cardiol; 2019 Jun; 73(24):e285-e350. PubMed ID: 30423393
    [No Abstract]   [Full Text] [Related]  

  • 15. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Grundy SM; Stone NJ; Bailey AL; Beam C; Birtcher KK; Blumenthal RS; Braun LT; de Ferranti S; Faiella-Tommasino J; Forman DE; Goldberg R; Heidenreich PA; Hlatky MA; Jones DW; Lloyd-Jones D; Lopez-Pajares N; Ndumele CE; Orringer CE; Peralta CA; Saseen JJ; Smith SC; Sperling L; Virani SS; Yeboah J
    J Am Coll Cardiol; 2019 Jun; 73(24):3168-3209. PubMed ID: 30423391
    [No Abstract]   [Full Text] [Related]  

  • 16. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events.
    Lee S; Cannon CP
    Curr Cardiol Rep; 2018 May; 20(7):55. PubMed ID: 29802475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of LDL-cholesterol after an acute coronary syndrome: Key comparisons of the American and European clinical guidelines to the attention of the healthcare providers.
    Gencer B; Giugliano RP
    Clin Cardiol; 2020 Jul; 43(7):684-690. PubMed ID: 32596859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol.
    Chuzi S; Pfenniger A; Lloyd-Jones DM; Blumenthal RS; Smith SC; Virani SS; Grundy SM; Stone NJ
    JAMA Cardiol; 2019 May; 4(5):473-477. PubMed ID: 30969319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.
    Sabatine MS; Giugliano RP
    JAMA Cardiol; 2017 Sep; 2(9):935-936. PubMed ID: 28768310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.